Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 3/2020

Open Access 01-02-2020 | Migraine | AdisInsight Report

Ubrogepant: First Approval

Author: Lesley J. Scott

Published in: Drugs | Issue 3/2020

Login to get access

Abstract

Ubrogepant (Ubrelvy™) is an orally administered, small molecule, highly-selective, calcitonin gene-related peptide (CGRP) antagonist that was developed by Allergan under license to Merck & Co. as an acute treatment for migraine. In December 2019, ubrogepant received its first global approval in the USA for the acute treatment of migraine (± aura) in adults. This article summarizes the milestones in the development of ubrogepant leading to its first global approval for the acute treatment of migraine (± aura) in adults.
Literature
1.
Holland PR, Goadsby PJ. Targeted CGRP small molecule antagonists for acute migraine therapy. Neurotherapeutics. 2018;15(2):304–12.CrossRef
2.
Chan C, Goadsby PJ. Recent advances in pharmacotherapy for episodic migraine. CNS Drugs. 2019;33(11):1053–71.CrossRef
3.
Edvinsson L, Haanes KA, Warfvinge K, et al. CGRP as the target of new migraine therapies—successful translation from bench to clinic. Nat Rev Neurol. 2018;14(6):338–50.CrossRef
4.
Allergan, Merck. Allergan enters into licensing agreement with Merck to obtain exclusive worldwide rights to CGRP migraine development program [media release]. 7 Jul 2015.
5.
6.
7.
Moore E, Burgey CS, Fraley M, et al. Characterization of ubrogepant: a potent and selective antagonist of the human calcitonin gene-related peptide receptor [abstract]. Headache. 2019;59(Suppl 1):89–90.
8.
Edvinsson L, Rubio-Beltran E, Chan K, et al. Characterization of the effects of the calcitonin gene-related peptide (CGRP) receptor antagonists, atogepant and ubrogepant, on isolated human coronary, cerebral, and middle meningeal arteries [abstract no. OR13]. Headache. 2019;59(Suppl 1):13.
9.
10.
Li C, Palcza J, Xu J, et al. Absence of clinically significant drug interactions with coadministration of ubrogepant and an ethinyl estradiol/norgestimate oral contraceptive in healthy female subjects: a phase 1 pharmacokinetic analysis [abstract no. P100]. Headache. 2019;59(Suppl 1):91.
11.
Jakate A, Boinpally R, Butler M, et al. Single therapeutic doses of ubrogepant are not associated with a clinically relevant drug-drug interaction when co-administered with acetaminophen or naproxen [abstract no. P96]. Headache. 2019;59(Suppl 1):87–8.
12.
Jakate A, Boinpally R, Butler M, et al. Coadministration of single therapeutic oral doses of ubrogepant and sumatriptan produces no clinically relevant pharmacokinetic interactions [abstract no. P95]. Headache. 2019;59(Suppl 1):86–7.
13.
Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the treatment of migraine. N Engl J Med. 2019;381(23):2230–41.CrossRef
14.
Lipton RB, Dodick DW, Ailani J, et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019;322(19):1887–98.CrossRef
15.
Dodick DW, Goadsby PJ, Lakkis H, et al. Ubrogepant achieves onset of pain relief at 1 hour for the acute treatment of migraine [abstract no. P103]. Headache. 2019;59(Suppl 1):92–3.
16.
Blumenfeld AM, Goadsby PJ, Dodick DW, et al. Ubrogepant is effective for the acute treatment of migraine in patients for whom triptans are ineffective [abstract no. IOR02]. Headache. 2019;59(Suppl 1):19.
17.
Ailani J, Blumenfeld AM, Klein B, et al. An optional second dose of ubrogepant is effective in achieving 2-hour pain freedom in the acute treatment of migraine [abstract no. P112]. Headache. 2019;59(Suppl 1):98.
18.
Voss T, Lipton RB, Dodick DW, et al. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia. 2016;36(9):887–98.CrossRef
19.
20.
Lipton RB, Ailani J, Hutchinson S, et al. Efficacy is maintained with long-term intermittent use of ubrogepant for the acute treatment of migraine [abstract no. P135]. Headache. 2019;59(Suppl 1):110.
21.
Ankrom W, Bondiskey P, Li CC, et al. Ubrogepant is not associated with clinically meaningful elevations of alanine aminotransferase in healthy adult males. Clin Transl Sci. 2020:1–11.
22.
Goadsby PJ, Tepper SJ, Watkins PB, et al. Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: randomized, placebo-controlled trial in healthy adults. Cephalalgia. 2019;39(14):1753–61.CrossRef
23.
Hutchinson S, Dodick DW, Treppendahl C, et al. Ubrogepant for the acute treatment of migraine: pooled safety and tolerability from ACHIEVE I and ACHIEVE II phase 3 studies [abstract no. P154]. Headache. 2019;59(Suppl 1):120.
24.
Hutchinson S, Silberstein SD, Blumenfeld AM, et al. Safety of ubrogepant in participants with moderate to high cardiovascular risk [abstract no. P124]. Headache. 2019;59(Suppl 1):104–5.
25.
Ailani J, Lipton RB, Hutchinson S, et al. Long-term safety evaluation of ubrogepant for the acute treatment of migraine; phase 3, randomized, 52-week extension trial. Headache. 2020;60:141–52.CrossRef
Metadata
Title
Ubrogepant: First Approval
Author
Lesley J. Scott
Publication date
01-02-2020
Publisher
Springer International Publishing
Keywords
Migraine
Aura
Published in
Drugs / Issue 3/2020
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-020-01264-5

Other articles of this Issue 3/2020

Drugs 3/2020 Go to the issue

Adis Drug Evaluation

Ramucirumab: A Review in Hepatocellular Carcinoma

Review Article

Potential of Lipoprotein(a)-Lowering Strategies in Treating Coronary Artery Disease

AdisInsight Report

Givosiran: First Approval

Review Article

Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent

AdisInsight Report

Golodirsen: First Approval

Review Article

Kratom (Mitragyna Speciosa) Liver Injury: A Comprehensive Review